LTPA2021528I1 - - Google Patents
Info
- Publication number
- LTPA2021528I1 LTPA2021528I1 LTPA2021528C LTPA2021528C LTPA2021528I1 LT PA2021528 I1 LTPA2021528 I1 LT PA2021528I1 LT PA2021528 C LTPA2021528 C LT PA2021528C LT PA2021528 C LTPA2021528 C LT PA2021528C LT PA2021528 I1 LTPA2021528 I1 LT PA2021528I1
- Authority
- LT
- Lithuania
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
- A61K39/39525—Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Analytical Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72197405P | 2005-09-30 | 2005-09-30 | |
GBGB0519923.7A GB0519923D0 (en) | 2005-09-30 | 2005-09-30 | Interleukin-13 antibody composition |
PCT/GB2006/003650 WO2007036745A2 (en) | 2005-09-30 | 2006-09-29 | Interleukin-13 antibody composition |
Publications (1)
Publication Number | Publication Date |
---|---|
LTPA2021528I1 true LTPA2021528I1 (lt) | 2021-12-27 |
Family
ID=37434894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTPA2021528C LTPA2021528I1 (lt) | 2005-09-30 | 2021-11-17 |
Country Status (20)
Country | Link |
---|---|
US (3) | US20080248048A1 (lt) |
EP (1) | EP1942939B2 (lt) |
JP (2) | JP2009510046A (lt) |
KR (1) | KR101363777B1 (lt) |
AU (1) | AU2006296399B2 (lt) |
BR (1) | BRPI0616359B8 (lt) |
CA (1) | CA2623429C (lt) |
CY (1) | CY1120874T1 (lt) |
FI (1) | FIC20210042I1 (lt) |
FR (1) | FR21C1055I2 (lt) |
GB (1) | GB2430883B (lt) |
HK (1) | HK1210724A1 (lt) |
HU (1) | HUS2100053I1 (lt) |
IL (3) | IL189983A (lt) |
LT (1) | LTPA2021528I1 (lt) |
NL (1) | NL301143I2 (lt) |
NO (2) | NO344859B1 (lt) |
PL (1) | PL1942939T5 (lt) |
SI (1) | SI1942939T2 (lt) |
WO (1) | WO2007036745A2 (lt) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8420086B2 (en) * | 2002-12-13 | 2013-04-16 | Immunomedics, Inc. | Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases |
AU2004308494B2 (en) | 2003-12-23 | 2010-03-18 | Genentech, Inc. | Novel anti-IL 13 antibodies and uses thereof |
EP2532677A1 (en) | 2005-10-21 | 2012-12-12 | Novartis AG | Human antibodies against il13 and therapeutic uses |
TWI392684B (zh) | 2006-04-05 | 2013-04-11 | Abbott Biotech Ltd | 抗體之純化 |
AR064826A1 (es) * | 2007-01-09 | 2009-04-29 | Wyeth Corp | Formulaciones de anticuerpos anti-il-13 y usos de los mismos. dispositivos, parche y jeringa |
WO2009002521A2 (en) * | 2007-06-25 | 2008-12-31 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
UA107557C2 (xx) * | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
EP2173163A4 (en) * | 2007-07-06 | 2010-12-08 | Glaxosmithkline Llc | ANTIBODY FORMULATIONS |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
JP6161233B2 (ja) | 2008-03-31 | 2017-07-12 | ジェネンテック, インコーポレイテッド | 喘息の治療及び診断のための組成物及び方法 |
GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
CN104744560A (zh) | 2009-10-20 | 2015-07-01 | Abbvie公司 | 使用蛋白a亲和色谱法分离和纯化抗-il-13抗体 |
CN105175542B (zh) | 2010-12-16 | 2018-12-18 | 弗·哈夫曼-拉罗切有限公司 | 与th2抑制相关的诊断和治疗 |
EP3235508B1 (en) | 2011-03-16 | 2020-12-30 | Sanofi | Compositions comprising a dual v region antibody-like protein |
JP2014510152A (ja) * | 2011-04-07 | 2014-04-24 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 粘度が低減された処方物 |
AU2012283039A1 (en) | 2011-07-13 | 2014-01-30 | Abbvie Inc. | Methods and compositions for treating asthma using anti-IL-13 antibodies |
EP4218937A3 (en) | 2011-10-31 | 2023-10-25 | F. Hoffmann-La Roche AG | Anti-il13 antibody formulations |
AR090339A1 (es) | 2012-03-27 | 2014-11-05 | Genentech Inc | Metodos de pronostico, diagnostico y tratamiento de la fibrosis pulmonar idiopatica |
US10023608B1 (en) | 2013-03-13 | 2018-07-17 | Amgen Inc. | Protein purification methods to remove impurities |
NZ756749A (en) | 2013-09-13 | 2022-05-27 | Genentech Inc | Methods and compositions comprising purified recombinant polypeptides |
EP4163633A1 (en) | 2013-09-13 | 2023-04-12 | F. Hoffmann-La Roche AG | Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products |
CN105849280B (zh) | 2013-10-23 | 2020-11-06 | 豪夫迈·罗氏有限公司 | 诊断和治疗嗜酸性粒细胞紊乱的方法 |
JP2014062100A (ja) * | 2013-11-05 | 2014-04-10 | Glaxosmithkline Llc | 抗体処方 |
BR112016018980A2 (pt) | 2014-02-21 | 2017-10-10 | Genentech Inc | método de tratamento de um distúrbio, anticorpo multiespecífico, ácido nucleico isolado, célula hospedeira, métodos de produzir um anticorpo, de produção de uma metade de anticorpo ou de um anticorpo multiespecífico e de produção de um anticorpo multiespecífico, imunoconjugado e formulação farmacêutica |
WO2015131153A1 (en) * | 2014-02-27 | 2015-09-03 | Board Of Regents, The University Of Texas System | Methods and compositions for isolating exosomes |
RU2694980C2 (ru) | 2014-04-11 | 2019-07-18 | Новартис Аг | Способы избирательного лечения астмы с использованием антагонистов il-13 |
JP6247241B2 (ja) * | 2015-02-27 | 2017-12-13 | ノバルティス アーゲー | 抗体処方 |
WO2016149276A1 (en) | 2015-03-16 | 2016-09-22 | Genentech, Inc. | Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases |
WO2017139290A1 (en) * | 2016-02-10 | 2017-08-17 | Medimmune, Llc | Tralokinumab delivery device |
EP3528838B1 (en) | 2016-09-23 | 2023-07-19 | F. Hoffmann-La Roche AG | Uses of il-13 antagonists for treating atopic dermatitis |
RU2019138507A (ru) | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1 |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
CA3226165A1 (en) | 2018-02-09 | 2019-08-15 | Genentech, Inc. | Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases |
WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
US20230287099A1 (en) | 2020-03-23 | 2023-09-14 | Medimmune Limited | Methods for treating atopic dermatitis and related disorders |
GB202108379D0 (en) | 2021-06-11 | 2021-07-28 | Medlmmune Ltd | Methods for treating a topic dermatitis and related disorders |
WO2023023497A1 (en) | 2021-08-16 | 2023-02-23 | Medimmune Llc | Anti-il-13 antibody formulation |
WO2023044313A1 (en) | 2021-09-15 | 2023-03-23 | Dermira, Inc. | Il-13 inhibitors for the treatment of prurigo nodularis |
WO2023052408A1 (en) | 2021-09-28 | 2023-04-06 | Medimmune Limited | Methods for treating atopic dermatitis and related disorders |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2685919B1 (fr) | 1992-01-08 | 1994-04-08 | Elf Sanofi | Proteine a activite de type cytokine, adn recombinant codant pour cette proteine, cellules animales transformees. |
EP0506574B1 (fr) * | 1991-03-29 | 1995-11-29 | Sanofi | Protéine à activité de type cytokine, ADN recombinant codant pour cette protéine, cellules et microorganismes transformés |
US5596072A (en) | 1992-08-21 | 1997-01-21 | Schering Corporation | Method of refolding human IL-13 |
JPH07267994A (ja) * | 1994-03-31 | 1995-10-17 | Snow Brand Milk Prod Co Ltd | 新規蛋白質及びその製造法 |
JP3414856B2 (ja) * | 1994-08-09 | 2003-06-09 | 株式会社ヤトロン | ジフェニルエーテル化合物の免疫学的測定方法 |
US5866154A (en) † | 1994-10-07 | 1999-02-02 | The Dupont Merck Pharmaceutical Company | Stabilized naloxone formulations |
US6428788B1 (en) * | 1995-03-15 | 2002-08-06 | Penn State University | Compositions and methods for specifically targeting tumors |
AU719513B2 (en) † | 1996-05-04 | 2000-05-11 | Astrazeneca Ab | Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system |
GB9610992D0 (en) | 1996-05-24 | 1996-07-31 | Glaxo Group Ltd | Concentrated antibody preparation |
JP3919235B2 (ja) | 1997-06-13 | 2007-05-23 | ジェネンテク,インコーポレイテッド | 抗体製剤 |
US6991790B1 (en) * | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
TR200100303T2 (tr) † | 1998-06-09 | 2001-06-21 | Statens Serum Institut | Damardan uygulanacak immünoglobülinler üretmek için yöntem ve başka immünoglobülin ürünleri. |
JP3537331B2 (ja) * | 1998-11-17 | 2004-06-14 | 積水化学工業株式会社 | Iv型コラーゲンの免疫測定法及び試薬 |
WO2001066754A1 (en) † | 2000-03-03 | 2001-09-13 | Cambridge Antibody Technology Limited | Human antibodies against eotaxin and their use |
EP1175931A1 (en) † | 2000-07-25 | 2002-01-30 | Computer Cell Culture Center S.A. | Integration of high cell density bioreactor operation with ultra fast on-line downstream processing |
WO2003010512A2 (en) † | 2001-07-23 | 2003-02-06 | Accurate Polymers, Inc. | High-speed, solid-liquid separation |
US20030235555A1 (en) | 2002-04-05 | 2003-12-25 | David Shealey | Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses |
US20040023337A1 (en) | 2001-10-26 | 2004-02-05 | Heavner George A. | IL-13 mutein proteins, antibodies, compositions, methods and uses |
US20040234499A1 (en) * | 2001-10-26 | 2004-11-25 | David Shealy | Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses |
US20040248260A1 (en) * | 2001-10-26 | 2004-12-09 | Heavner George A. | IL-13 mutein proteins, antibodies, compositions, methods and uses |
CA2490423A1 (en) * | 2002-06-21 | 2003-12-31 | Biogen Idec Inc. | Buffered formulations for concentrating antibodies and methods of use thereof |
PT1601697E (pt) † | 2003-02-28 | 2007-09-04 | Lonza Biologics Plc | Purificação de anticorpos através de proteína a e cromatografia de troca iónica. |
JPWO2004087761A1 (ja) † | 2003-03-31 | 2006-07-27 | 麒麟麦酒株式会社 | ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製 |
SI2335725T1 (sl) * | 2003-04-04 | 2017-01-31 | Genentech, Inc. | Visokokoncentrirane formulacije protiteles in proteinov |
GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
TW200530269A (en) * | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Anti-Mpl antibodies |
AU2004308494B2 (en) † | 2003-12-23 | 2010-03-18 | Genentech, Inc. | Novel anti-IL 13 antibodies and uses thereof |
CN1234725C (zh) † | 2004-04-07 | 2006-01-04 | 陈志南 | 一种高效快速纯化制备片段抗体的方法 |
AR049390A1 (es) † | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
US20060039910A1 (en) * | 2004-08-20 | 2006-02-23 | Amgen Inc. | Methods and compositions for treating allergic inflammation |
EP1824886B1 (en) * | 2004-11-17 | 2010-12-22 | Amgen Inc. | Fully human monoclonal antibodies to il-13 |
US20060171943A1 (en) * | 2005-02-01 | 2006-08-03 | Amgen Inc. | Compositions and methods of treating fibrotic disorders |
EP2652038A1 (en) † | 2010-10-14 | 2013-10-23 | Ticona GmbH | Plasticized polyoxymethylene |
-
2006
- 2006-09-29 EP EP06794604.6A patent/EP1942939B2/en active Active
- 2006-09-29 AU AU2006296399A patent/AU2006296399B2/en active Active
- 2006-09-29 KR KR1020087010374A patent/KR101363777B1/ko active IP Right Grant
- 2006-09-29 JP JP2008532878A patent/JP2009510046A/ja active Pending
- 2006-09-29 PL PL06794604T patent/PL1942939T5/pl unknown
- 2006-09-29 CA CA2623429A patent/CA2623429C/en not_active Expired - Fee Related
- 2006-09-29 WO PCT/GB2006/003650 patent/WO2007036745A2/en active Application Filing
- 2006-09-29 SI SI200632277T patent/SI1942939T2/sl unknown
- 2006-09-29 BR BRPI0616359A patent/BRPI0616359B8/pt active IP Right Grant
- 2006-09-29 US US12/067,120 patent/US20080248048A1/en not_active Abandoned
- 2006-09-29 GB GB0619204A patent/GB2430883B/en active Active
-
2008
- 2008-03-06 IL IL189983A patent/IL189983A/en active IP Right Grant
- 2008-04-23 NO NO20081946A patent/NO344859B1/no active Protection Beyond IP Right Term
-
2010
- 2010-12-13 US US12/966,377 patent/US9107945B2/en active Active
-
2013
- 2013-10-10 JP JP2013212846A patent/JP5820450B2/ja active Active
- 2013-12-17 IL IL230005A patent/IL230005A/en active IP Right Grant
-
2015
- 2015-07-14 US US14/798,685 patent/US10358488B2/en active Active
- 2015-11-27 HK HK15111703.8A patent/HK1210724A1/xx unknown
-
2016
- 2016-07-10 IL IL246674A patent/IL246674B/en active IP Right Grant
-
2018
- 2018-07-20 CY CY181100758T patent/CY1120874T1/el unknown
-
2021
- 2021-11-03 NL NL301143C patent/NL301143I2/nl unknown
- 2021-11-12 NO NO2021050C patent/NO2021050I1/no unknown
- 2021-11-16 FR FR21C1055C patent/FR21C1055I2/fr active Active
- 2021-11-17 LT LTPA2021528C patent/LTPA2021528I1/lt unknown
- 2021-11-23 FI FIC20210042C patent/FIC20210042I1/fi unknown
- 2021-12-02 HU HUS2100053C patent/HUS2100053I1/hu unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LTPA2021528I1 (lt) | ||
BE2012C042I2 (lt) | ||
BRPI0601358B8 (pt) | Aplicador de clipe cirúrgico | |
BRPI0601402B8 (pt) | Aplicador de grampos cirúrgicos | |
BR122017004707A2 (lt) | ||
BRPI0609157A8 (lt) | ||
BRPI0608519A2 (lt) | ||
BR122020005056A2 (lt) | ||
AP2140A (lt) | ||
JP2006221567A5 (lt) | ||
BR122016029989A2 (lt) | ||
BRPI0604219A (lt) | ||
JP2006307975A5 (lt) | ||
JP2006236469A5 (lt) | ||
JP2006234679A5 (lt) | ||
JP2007020008A5 (lt) | ||
BRPI0618215B8 (lt) | ||
JP2006337915A5 (lt) | ||
JP2007057717A5 (lt) | ||
BY2237U (lt) | ||
JP2006250636A5 (lt) | ||
JP2006229361A5 (lt) | ||
JP2007032280A5 (lt) | ||
JP2006303222A5 (lt) | ||
JP2006292149A5 (lt) |